

A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers

NCT07215923

Status	RECRUITING
Phase	Phase 1
Sponsor	Antidote Therapeutics, Inc
Enrollment	15 participants

Key Eligibility Criteria

Inclusion (15)

- Provides written informed consent before any study procedures
 - Age 23 to 59 years, inclusive
 - Body weight ≥ 50 kg at Screening
 - Body mass index (BMI) 18.5-29.9 kg/m² at Screening
 - In good health with no medically significant conditions, in the opinion of the Investigator
- ... and 10 more (see full listing online)

Exclusion (26)

- Pregnant, breastfeeding, or planning pregnancy
 - Positive serum pregnancy test at Screening or urine pregnancy test on Day -2 (women only)
 - Prior exposure to any anti-nicotine vaccine or antibody
 - Use of mentholated tobacco products within 30 days before Screening, unwilling to refrain during the study
 - History of severe allergic reaction to antibodies or vaccines (including Guillain-Barré syndrome)
- ... and 21 more (see full listing online)

Locations (1 total)

Dr. Vince Clinical Research, Overland Park, Kansas, United States